EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) PET / CT for lymph node assessment before radical cystectomy in bladder cancer patients

Mattia Longoni iD, Pietro Scilipoti, Chiara Re, Giuseppe Rosiello, Luigi Nocera iD, Francesco Pellegrino iD, Giuseppe Basile, Mario de Angelis iD, Leonardo Quarta, Giusy Burgio, Andrea Necchi, Antonio Cigliola und 6 weitere

BJU International · 2024

DOI: 10.1111/bju.16363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2024. Verfasst von Mattia Longoni und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Fluorodeoxyglucose F18, Cystectomy, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). Materials and Methods This analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) was administered after oncological evaluation. All patients received preoperative 18F‐FDG PET/CT to assess extravesical disease. Point estimates for true negative, false negative, false positive, true positive, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of conventional imaging and PET/CT were calculated. Subgroup analysis in patients receiving neoadjuvant treatment was performed.

Results

At preoperative evaluation, 30 patients (15.1%) had 48 suspicious nodal spots on 18F‐FDG PET/CT. At RC and bilateral PLND, a total of 4871 lymph nodes (LNs) were removed with 237 node metastases corresponding to 126 different regions. Pathological node metastases were found in 17/30 (57%) vs 39/169 patients (23%) with suspicious vs negative preoperative 18F‐FDG PET/CT, respectively (sensitivity = 0.30, specificity = 0.91, PPV = 0.57, NPV = 0.77, accuracy = 0.74). On per‐region analysis including 1367 nodal regions, LN involvement was found in 19/48 (39%) vs 105/1319 (8%) suspicious vs negative regions at PET/CT, respectively (sensitivity = 0.15, specificity = 0.98, PPV = 0.40, NPV = 0.92, ACC = 0.90). Similar results were observed for patients receiving NAC ( n = 44, 32.1%) and NAI ( n = 93, 67.9% [per‐patient: sensitivity = 0.36, specificity = 0.91, PPV = 0.59, NPV = 0.80, accuracy = 0.77; per‐region: sensitivity = 0.12, specificity = 0.98, PPV = 0.32, NPV = 0.93, ACC = 0.91]). Study limitations include its retrospective design and limited patient numbers.

Conclusions

In eight out of 10 patients with negative preoperative 18F‐FDG PET/CT, pN0 disease was confirmed at final pathology. No differences were found based on NAC vs NAI treatment. These findings suggest that 18F‐FDG PET/CT could play a role in the preoperative evaluation of nodal metastases in BCa patients, although its cost‐effectiveness is uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsFluorodeoxyglucose F18CystectomyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsHumansMaleFemaleAgedMiddle AgedLymphatic MetastasisLymph Node ExcisionLymph NodesRetrospective StudiesPreoperative CareAged, 80 and overAdultNeoadjuvant TherapyNeoplasm Staging

Stichwörter der Autor:innen

18F‐FDGPET/CTbladder cancerlymph nodeneoadjuvant therapypelvic lymph node dissectionradical cystectomystaging

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Department of Nuclear Medicine, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.

ORCID-Profile: Mattia Longoni, Luigi Nocera, Francesco Pellegrino, Mario de Angelis, Andrea Salonia, Francesco Montorsi, Marco Moschini

Zitieren

APA

Longoni, M., Scilipoti, P., Re, C., Rosiello, G., Nocera, L., Pellegrino, F., Basile, G., de Angelis, M., Quarta, L., Burgio, G., Necchi, A., Cigliola, A., Chiti, A., Picchio, M., Salonia, A., Briganti, A., Montorsi, F., & Moschini, M. (2024). Use of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) PET / CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU International. https://doi.org/10.1111/bju.16363

Vancouver

Longoni M, Scilipoti P, Re C, Rosiello G, Nocera L, Pellegrino F, et al. Use of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) PET / CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU International. 2024. doi:10.1111/bju.16363

BibTeX
@article{Longoni2024,
  author = {Longoni, Mattia and Scilipoti, Pietro and Re, Chiara and Rosiello, Giuseppe and Nocera, Luigi and Pellegrino, Francesco and Basile, Giuseppe and de Angelis, Mario and Quarta, Leonardo and Burgio, Giusy and Necchi, Andrea and Cigliola, Antonio and Chiti, Arturo and Picchio, Maria and Salonia, Andrea and Briganti, Alberto and Montorsi, Francesco and Moschini, Marco},
  title = {Use of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) PET / CT for lymph node assessment before radical cystectomy in bladder cancer patients},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16363}
}
Kostenlos starten →